XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3
RESTRUCTURING
 9 Months Ended
Sep. 30, 2024
Restructuring Charges [Abstract]  
RESTRUCTURING RESTRUCTURING
2023 Restructuring Plan

In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities. Consistent with our prioritization and efficiency goals communicated earlier this year, BMS continues to execute on strategic productivity initiatives through portfolio prioritization and management of our operating costs. Total expected restructuring costs under the 2023 Restructuring Plan to be incurred through 2026 are approximately $1.5 billion. These costs consist primarily of employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.

Celgene and Other Acquisition Plans

Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). For these plans, the remaining charges of approximately $350 million consist primarily of employee termination costs, IT system integration costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.
The following provides the charges related to restructuring initiatives by type of cost:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2024202320242023
2023 Restructuring Plan$180 $149 $512 $380 
Celgene and Other Acquisition Plans83 131 420 269 
Total charges$263 $280 $932 $649 
Employee termination costs$77 $135 $554 $309 
Other termination costs1 6 4 12 
Provision for restructuring78 141 558 321 
Integration expenses69 54 214 180 
Accelerated depreciation22 15 56 28 
Asset impairments (a)
93 70 95 120 
Other shutdown costs
1 — 9 — 
Total charges$263 $280 $932 $649 
Cost of products sold$88 $16 $105 $53 
Marketing, selling and administrative7 65 19 85 
Research and development21 4 36 10 
Other (income)/expense, net147 195 772 501 
Total charges$263 $280 $932 $649 
(a)    Includes $87 million for a site impairment incurred during the three months ended September 30, 2024 and a $65 million impairment charge for a facility lease during the three months ended September 30, 2023.

The following summarizes the charges and spending related to restructuring plan activities:
Nine Months Ended September 30,
Dollars in millions20242023
Beginning balance $188 $47 
Provision for restructuring558 321 
Foreign currency translation and other— (3)
Payments(432)(142)
Ending balance$314 $223